[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017003463A - Inhibidores de histona desmetilasa. - Google Patents

Inhibidores de histona desmetilasa.

Info

Publication number
MX2017003463A
MX2017003463A MX2017003463A MX2017003463A MX2017003463A MX 2017003463 A MX2017003463 A MX 2017003463A MX 2017003463 A MX2017003463 A MX 2017003463A MX 2017003463 A MX2017003463 A MX 2017003463A MX 2017003463 A MX2017003463 A MX 2017003463A
Authority
MX
Mexico
Prior art keywords
cancer
compositions
histone demethylase
compounds
useful
Prior art date
Application number
MX2017003463A
Other languages
English (en)
Inventor
K Chen Young
Brennan Wallace Michael
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2017003463A publication Critical patent/MX2017003463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona generalmente a composiciones y métodos para tratar cáncer y enfermedad neoplastica. Se proporciona en la presente compuertos derivados de pirrolopiridina sustituidos y composiciones farmacéuticas que comprenden los compuestos. Los presentes compuestos y composiciones son útiles para la inhibición de histonia desmetilasa. Además, los presentes compuestos y composiciones son utilies para el tratamiento de cáncer, tales como cáncer de próstata, cáncer de seno, cáncer de vejiga, cáncer de pulmón y/o melanoma y los similares.
MX2017003463A 2014-09-17 2015-09-14 Inhibidores de histona desmetilasa. MX2017003463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051850P 2014-09-17 2014-09-17
PCT/US2015/049926 WO2016044138A1 (en) 2014-09-17 2015-09-14 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
MX2017003463A true MX2017003463A (es) 2017-07-13

Family

ID=55533717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003463A MX2017003463A (es) 2014-09-17 2015-09-14 Inhibidores de histona desmetilasa.

Country Status (17)

Country Link
US (3) US9758517B2 (es)
EP (1) EP3194387B1 (es)
JP (2) JP6723663B2 (es)
KR (1) KR20170048601A (es)
CN (1) CN107001330A (es)
AU (1) AU2015318111A1 (es)
BR (1) BR112017005510A2 (es)
CA (1) CA2961580A1 (es)
CL (1) CL2017000662A1 (es)
CO (1) CO2017003445A2 (es)
EA (1) EA201790604A1 (es)
EC (1) ECSP17022542A (es)
ES (1) ES2751464T3 (es)
IL (1) IL251184A0 (es)
MX (1) MX2017003463A (es)
SG (1) SG11201702119PA (es)
WO (1) WO2016044138A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
MX2017003463A (es) * 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018188590A1 (en) * 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
CN109709333B (zh) * 2018-08-01 2021-09-24 东南大学 H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2006311767A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN101553223A (zh) 2006-12-04 2009-10-07 诺瓦提斯公司 Hdac抑制剂和抗代谢物的组合
JP2010526048A (ja) 2007-05-04 2010-07-29 アストラゼネカ アクチボラグ アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
WO2011058474A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
US9988377B2 (en) 2011-08-24 2018-06-05 The Trustees Of Columbia University In The City Of New York Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders
ES2617905T3 (es) * 2012-10-02 2017-06-20 Gilead Sciences, Inc Inhibidores de desmetilasas de histonas
AU2013361255B2 (en) 2012-12-19 2017-01-05 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
MX2017003463A (es) * 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.

Also Published As

Publication number Publication date
CA2961580A1 (en) 2016-03-24
SG11201702119PA (en) 2017-04-27
KR20170048601A (ko) 2017-05-08
AU2015318111A1 (en) 2017-04-13
EA201790604A1 (ru) 2017-09-29
EP3194387A4 (en) 2018-03-07
US20160108032A1 (en) 2016-04-21
JP6723663B2 (ja) 2020-07-15
JP6967632B2 (ja) 2021-11-17
CN107001330A (zh) 2017-08-01
US20180271843A1 (en) 2018-09-27
EP3194387B1 (en) 2019-07-31
WO2016044138A1 (en) 2016-03-24
JP2020169183A (ja) 2020-10-15
JP2017529347A (ja) 2017-10-05
IL251184A0 (en) 2017-05-29
BR112017005510A2 (pt) 2018-08-14
ES2751464T3 (es) 2020-03-31
US10231957B2 (en) 2019-03-19
US20170326116A1 (en) 2017-11-16
US9758517B2 (en) 2017-09-12
EP3194387A1 (en) 2017-07-26
CO2017003445A2 (es) 2017-07-11
ECSP17022542A (es) 2017-05-31
CL2017000662A1 (es) 2018-03-23
US10016401B2 (en) 2018-07-10

Similar Documents

Publication Publication Date Title
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
TW201613882A (en) Histone demethylase inhibitors
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX2017003464A (es) Inhibidores de histona desmetilasa.
MX2017003466A (es) Inhibidores de histona desmetilasa.
MX2017003463A (es) Inhibidores de histona desmetilasa.